Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review

Clinical Effects of Immuno-Oncology Therapy on Glioblastoma Patients: A Systematic Review

The most prevalent and deadly primary malignant glioma in adults is glioblastoma (GBM), which has a median survival time of about 15 months. Despite the standard of care for glioblastoma, which includes gross total resection, high-dose radiation, and temozolomide chemotherapy, this tumor is still on...

Full description

Bibliographic Details
Main Authors: Masoumeh Najafi, Amin Jahanbakhshi, Sebastiano Finocchi Ghersi, Lucia Giaccherini, Andrea Botti, Francesco Cavallieri, Jessica Rossi, Federico Iori, Cinzia Iotti, Patrizia Ciammella, Mohsen Nabiuni, Marzieh Gomar, Omid Rezaie, Salvatore Cozzi
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Brain Sciences
Subjects:
immunotherapy
chemotherapy
radiotherapy
glioblastoma
GBM
temozolomide
Online Access:https://www.mdpi.com/2076-3425/13/2/159

Internet

https://www.mdpi.com/2076-3425/13/2/159

Similar Items